August 28, 2007 - CryoCor Inc., a medical device company focused on the treatment of cardiac arrhythmias, announced the completion of enrollment of its clinical study for the use of ablation for the treatment of atrial fibrillation.
CryoCor has enrolled over 170 patients in its clinical study and will complete a 12-month follow up for each patient. Completion of enrollment of atrial fibrillation ablation trials brings the company closer to bringing its product to market for treating atrial fibrillation.
With the recent approval of its cryoablation system for the treatment of right atrial flutter, the company will begin placing its system at high volume ablation centers across the U.S. CryoCor anticipates approval for the treatment of atrial fibrillation in 2009.
For more information: www.cryocor.com
October 30, 2024 
